Summarized by Daily Strand AI from peer-reviewed source
Cancer patients often face a dangerous but hidden complication: blood clots. A recent scientific review highlights that female-specific cancers, such as ovarian and breast cancer, carry unique risks for these blockages, known medically as venous thromboembolism. Ovarian cancer carries the highest incidence of these clots among female-specific malignancies. This heightened danger is primarily driven by advanced disease, abdominal fluid buildup, and platinum-based chemotherapy.
Breast cancer is also heavily impacted by this issue, accounting for roughly 15 percent of all cancer-associated blood clot cases. This risk climbs even higher when patients take certain targeted treatments, such as selective estrogen receptor modulators or CDK4/6 inhibitors. To combat this, doctors use preventive strategies called prophylaxis. They prescribe specific blood thinners, like low-molecular-weight heparins or direct oral anticoagulants, which successfully reduce the occurrence of clots in high-risk individuals.
For patients needing extended protection, recent research offers promising news. A major study called the API-CAT trial looked at patients taking a blood thinner called apixaban. The trial demonstrated that dropping to a reduced dose of 2.5 milligrams twice daily was just as effective as a full dose for keeping clots away after a patient has completed six months of standard treatment.
Blood clots remain a leading cause of severe illness and death for cancer patients. By recognizing that breast cancer alone makes up roughly 15 percent of cancer-associated thrombosis cases, and that ovarian cancer patients face a clot incidence between 5 and 14 percent, doctors can be much more proactive. The success of the API-CAT trial is a major victory for patient quality of life. It proves that patients can maintain long-term protection on a lower dose, which helps minimize exposure to heavy medication while keeping them safe.
However, managing these risks requires a delicate balance. The research emphasizes a major clinical limitation: doctors must highly individualize blood thinner selections for every patient. Cancer therapies like doxorubicin, ribociclib, and tamoxifen can dangerously interact with blood thinners, and there is always an underlying risk of excessive bleeding. By closely monitoring these drug interactions, medical teams can safely protect women from both their cancer and the life-threatening clots it can cause.
Interested in Oncology?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.